ArticleInternational journal of cancer2018
Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women.Human reproduction (Oxford, England) · 2022Pooled it
- PCOS and breast cancer risk: hormonal modulation and epidemiological trends.Reproductive health · 2026Review
- Anti-Müllerian hormone plays a bidirectional role in cancer: a multi-database and multi-method study.Discover oncology · 2025Article
- Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women.Breast cancer research : BCR · 2025Article
- Current trends in breast cancer genetics, risk factors, and screening strategies.Journal of biological methods · 2025Review
- Circulating anti-Müllerian hormone levels in pre-menopausal women: novel genetic insights from a genome-wide association meta-analysis.Human reproduction (Oxford, England) · 2024Article
- DDIT3 is associated with breast cancer prognosis and immune microenvironment: an integrative bioinformatic and immunohistochemical analysis.Journal of Cancer · 2024Article
- Causal pathways linking polycystic ovary syndrome to distinct breast cancer subtypes through mediator factors: a multivariable mendelian randomization analysis.Journal of ovarian research · 2023Article
- The roles of anti-Müllerian hormone in breast cancer.Endocrine-related cancer · 2023Review
- Breast cancer risk coordinators: Artificial intelligence-based density measurement and Mullerian-inhibiting substance.Irish journal of medical science · 2023Article
- Goodness-of-fit two-phase sampling designs for time-to-event outcomes: a simulation study based on New York University Women's Health Study for breast cancer.BMC medical research methodology · 2023Article
- Inflammatory Responses of Women with Polycystic Ovary SyndromeInternational journal of molecular and cellular medicine · 2023Article
- Anti-Müllerian hormone levels and breast cancer risk in the study of women's health across the nation.Cancer causes & control : CCC · 2022Article
- Recombinant anti-Müllerian hormone in the maturation medium improves the in vitro maturation of human immature (GV) oocytes after controlled ovarian hormonal stimulation.Reproductive biology and endocrinology : RB&E · 2022Article
- Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women.The Journal of clinical endocrinology and metabolism · 2021Article
- Cancer Progress and Priorities: Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Review
- Article
- Abnormal anti-Müllerian hormone level may be a trigger for breast cancer in young women: A case-control study.International journal of reproductive biomedicine · 2021Article
- Empirical evaluation of sub-cohort sampling designs for risk prediction modeling.Journal of applied statistics · 2021Article
- Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium.Breast cancer research and treatment · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 4 countries.
Funding
Abstract
A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case-control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH was measured using a high sensitivity enzyme-linked immunoabsorbent assay. Conditional logistic regression was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk with increasing AMH concentration (p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.